Prosecution Insights
Last updated: November 04, 2026
Application No. 18/015,002

SATRAPLATIN FOR USE IN THE TREATMENT OF LYMPHOID NEOPLASMS

Non-Final OA §102
Filed
Jan 06, 2023
Priority
Jul 08, 2020 — EU 20184760.5 +1 more
Examiner
WILSON, JERICA KATLYNN
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pharma& Schweiz GmbH
OA Round
3 (Non-Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
72 granted / 122 resolved
-1.0% vs TC avg
Strong +38% interview lift
Without
With
+37.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
33 currently pending
Career history
156
Total Applications
across all art units

Statute-Specific Performance

§101
4.3%
-35.7% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
27.7%
-12.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 122 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 25 June 2026 has been entered. Status of the Claims Claims 1-2, 14-18, and 23-26 are pending in the instant application. Claim 1 has been amended. Claims 1-2, 14-18, and 23-26 are examined herein. Priority The instant application claims benefit of foreign priority to EP20184760, filed on 08 July 2020, and the benefit of priority to PCT/EP2021/065313, filed on 08 July 2021. The claims to the benefit of priority are acknowledged. As such, the effective filing date of the claims is 08 July 2020. Information Disclosure Statement The information disclosure statements (IDS), submitted on 06 January 2023. 12 March 2024, 20 February 2025, 25 April 2025, 25 April 2025, 25 June 2026, and 06 July 2026, are acknowledged and considered. The submissions are in compliance with the provisions of 37 CFR 1.97. Response to Arguments The amendment filed on 25 June 2026 has been entered. In view of applicant arguments, the 103 rejection of record is withdrawn. In addition, new 102(a)(1) rejections are necessitated by request for continued examination below. All rejections and objections not found below have been withdrawn. NEW REJECTIONS NECESSITATED BY RCE Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 14-18, and 23-26 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pollard et al. (US20180303829A1). Regarding claim 1, Pollard discloses a method of treating a proliferative disorder, including primary CNS lymphoma (paragraph [0296], in a subject comprising administering a DNA damaging agent (claim 1) wherein the DNA damaging agent is satraplatin (claim 4). Pollard further discloses administering an ATR kinase, based on the broadest reasonable interpretation of the “comprising” language of the instant claim 1, the additional therapeutic falls within the instant limitation. Regarding claim 2, Pollard discloses the subject to be human (paragraph [0302]. Regarding claim 14, Pollard (paragraph [0309]) teach the oral administration of satraplatin. Regarding claims 15 and 23, Pollard discloses the dose between 0.001 mg/kg to 1000 mg/kg, which is .037 mg/m2 to 37000 mg/m2, encompassing the claimed dose range. One skilled in the art would be expected to optimize the frequency of the dose. (Conversion Factors compiled from Cancer Chemother Rep.1966;50(4):219-244.) Regarding claims 16, 25, and 26, Pollard discloses the method for the treatment of solid tumor cancers (paragraph [0009]. Treatment of a solid tumor would result in death of tumor cells or inhibition of growth. Regarding claim 17, Pollard discloses the method of administering a DNA damaging agent with an ATR kinase inhibitor (claim 1). Regarding claim 18, Pollard does not disclose the co-administration of a DNA damaging agent and another therapeutic agent however, combination therapy is well known in the art, as is concurrent administration. It would be prima facie obvious to one of ordinary skill in the art to administer satraplatin concurrently with an additional agent with a reasonable expectation of success as Pollard demonstrates a successful combination therapy. Regarding claim 24, Pollard discloses an effective amount of a compound is an amount necessary to ameliorate or reverse one of more symptoms of the proliferative disease (paragraph [0307]). Conclusion Claims 1-2, 14-18, and 23-26 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerica K Wilson whose telephone number is (703)756-4690. The examiner can normally be reached Monday-Friday 9:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.K.W./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 17, 2025
Response after Non-Final Action
Aug 08, 2025
Non-Final Rejection mailed — §102
Nov 07, 2025
Response Filed
Nov 07, 2025
Response after Non-Final Action
Feb 25, 2026
Final Rejection mailed — §102
Jun 25, 2026
Request for Continued Examination
Jun 29, 2026
Response after Non-Final Action
Sep 16, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780845
ARGINASE INHIBITORS AND METHODS OF USE
4y 4m to grant Granted Nov 03, 2026
Patent 12780808
NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES
3y 8m to grant Granted Nov 03, 2026
Patent 12759971
ACETONITRILE PURIFICATION PROCESS FOR ULTRAHIGH PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETER
3y 7m to grant Granted Oct 13, 2026
Patent 12758563
PHARMACEUTICAL COMPOUNDS AND METHODS OF USE
4y 6m to grant Granted Oct 13, 2026
Patent 12758541
PHARMACEUTICALLY ACCEPTABLE SALT OF CARIPRAZINE AND CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 7m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
96%
With Interview (+37.5%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month